Livzon Pharmaceutical Group Inc.: history, ownership, mission, how it works & makes money

From its founding in 1985 to its Hong Kong Stock Exchange listing as 1513.HK in 1997, Livzon Pharmaceutical Group has grown into a vertically integrated pharma player with a product mix spanning leuprorelin acetate microspheres, urofollitropin, menotropins, Ilaprazole tablets, bismuth potassium citrate and a broad API portfolio (vancomycin, daptomycin, ceftriaxone sodium and more), delivering 11.81 billion CNY in revenue in 2024 (a 4.97% decline year‑on‑year) while pursuing international registrations, diagnostics, and an expanding biotech push highlighted by a RMB1 billion capital injection in March 2025 that raised its LivzonBio stake to 66.54%; corporate finance metrics show about 892.78 million shares outstanding, a market capitalization of HKD 33.09 billion (Dec 12, 2025), insider ownership of ~0.39%, institutional holdings of ~14.92%, a Sep 2025 buyback of 15.3768 million A‑shares (1.70% of capital), a trailing P/E of 14.13 and forward P/E of 13.57, and operational momentum with net profit attributable to the parent of 1.754 billion yuan (+4.86% YoY) and revenue of 9.116 billion yuan (+0.38% YoY) in the first three quarters of 2025 as the company balances shareholder returns (final cash dividend HKD 14.8203 per 10 shares for 2023) with R&D‑led growth including plans for generics like semaglutide and a global deployment strategy targeting emerging and developed markets.

Livzon Pharmaceutical Group Inc. (1513.HK): Intro

• Founded in 1985 with a focus on R&D, production and sales of pharmaceuticals and active pharmaceutical ingredients (APIs) for domestic and international markets.
• Listed on the Hong Kong Stock Exchange in 1997 under ticker 1513.HK, gaining access to international capital markets.
• Expanded over decades into multiple therapeutic areas and dosage forms, including innovative biologics and GI, reproductive and anti-infective products.

• Leuprorelin acetate microspheres (oncology/endocrinology)
• Urofollitropin and menotropins for injection (reproductive medicine)
• Ilaprazole enteric‑coated tablets (gastrointestinal)
• Bismuth potassium citrate products (anti‑infective/GI)

• Parent: Livzon Pharmaceutical Group Inc. is the listed holding entity; it owns a controlling stake in biotech subsidiary LivzonBio (66.54% as of March 2025).
• Capital structure: Listed equity on HKEX (1513.HK) provides public float and institutional investors; company has used both equity and cash to invest in strategic subsidiaries.

• Mission: Develop and commercialize safe, effective pharmaceutical products and APIs to meet clinical needs domestically and abroad.
• R&D: Investment in biologics and specialty small molecules, in‑house development of APIs and finished dosage forms, plus clinical development and regulatory submissions for new indications and formulations.
• Operations: Integrated model covering API manufacture, formulation, packaging and distribution across hospitals, pharmacies and distributors.

• Product sales: Revenue from finished drugs (branded generics, specialty products) sold to hospitals, clinics and distributors.
• API sales: Manufacturing and selling active pharmaceutical ingredients to internal and external customers.
• Biotech investment returns: Consolidation and scaling of subsidiaries like LivzonBio to capture growth in biologics and higher‑margin products.
• Licensing and partnerships: Out‑licensing technologies, co‑development and commercialization agreements (domestic and international).

• March 2025: Strengthened biotech exposure by increasing LivzonBio stake to 66.54% via RMB 1 billion investment, signaling focus on biologics growth.
• June 2024: Announced a meaningful cash dividend (HKD 14.8203 per 10 shares for FY2023), indicating shareholder return priority despite a slight revenue decline in 2024.
• 2024 revenue of CNY 11.81 billion (down 4.97% YoY) highlights short‑term pressure on sales while strategic investments continue.

Livzon Pharmaceutical Group Inc. (1513.HK): History

• Public listing: Hong Kong Stock Exchange, ticker 1513.HK, accessible to institutional and retail investors.
• Shares outstanding (Nov 2025): 892.78 million.
• Market capitalization (Nov 2025): HKD 33.09 billion.
• Insider ownership: ~0.39% (relatively low executive control).
• Institutional ownership: ~14.92% (moderate institutional interest).
• Share repurchase (Sep 2025): 15.3768 million A-shares repurchased (1.70% of total share capital).
• Dividend policy: shareholder-oriented; final cash dividend declared June 2024.

• Product sales: prescription drugs (injectables, oral solids), biologics and specialty therapies sold in China and export markets.
• R&D commercialization: internal pipeline products progressed to market capture higher-margin sales.
• Out-licensing and partnerships: collaboration revenues and milestone payments from international partners.
• Manufacturing and contract services: revenue from toll manufacturing and API supply.

Livzon Pharmaceutical Group Inc. (1513.HK): Ownership Structure

• Mission focus: prioritize unmet clinical needs through R&D investment and global patient access initiatives.
• Access & IP stance: supports compulsory licensing in public-interest emergencies and considers voluntary licensing to improve access in low-income markets.
• Environmental & social priorities: green operations, human welfare programs and responsible supply-chain governance per 2024 ESG reporting.

• Governance implications: promoter stake supports continuity in long-term R&D programs and strategic licensing policies.
• Market liquidity & access: public float sustains tradability on the HKEX and enables institutional engagement on ESG targets.

Livzon Pharmaceutical Group Inc. (1513.HK): Mission and Values

• Research & Development: Centralized R&D hubs focus on new chemical entities, biologics, vaccines and diagnostic reagents with an emphasis on addressing unmet clinical needs and differentiated global deployment.
• Manufacturing: Multiple GMP-certified production sites produce active pharmaceutical ingredients (APIs), finished dosage forms, biologics (including vaccines) and diagnostic kits, ensuring capacity for both on-patent medicines and generics.
• Commercialization: A combined direct-sales force, distributor partnerships and licensing arrangements cover domestic and international markets, supported by regulatory and market-access teams for overseas registrations.

• Chemical drug preparations: antibiotics, cardiovascular drugs, central nervous system agents, gastrointestinal products and others.
• Biological products: vaccines, monoclonal antibodies and recombinant proteins tailored for infectious disease and specialty indications.
• Traditional Chinese medicine (TCM) preparations: standardized TCM formulations for a range of indications.
• Diagnostic reagents and equipment: immunoassays, molecular diagnostics and companion diagnostic reagents used in hospitals and labs.

• Direct operations: regional subsidiaries and local sales teams in selected markets.
• License cooperation: out-licensing of assets, in-licensing to fill portfolio gaps, and co-development partnerships.
• Equity investments: minority stakes or JV structures to secure distribution channels, regulatory support and local manufacturing where needed.

• Balanced pipeline of biologics, vaccines and small molecules with staged global deployment (China-first then selective overseas filings).
• Clinical development aligned to regulatory pathways in target markets to accelerate approvals.
• Investment in diagnostics and companion tests to support precision medicine approaches for its therapeutics.

• Product sales: primary revenue from domestic and international sales of prescription drugs, vaccines, TCM products and diagnostics.
• API and contract manufacturing: income from supplying APIs and undertaking third-party manufacturing for other pharma companies.
• Licensing & royalties: upfronts, milestones and royalties from out-licensing deals and co-development partnerships.
• Exports & tender wins: revenues from government tenders and institutional procurement in emerging markets for vaccines and generics.
• Diagnostics & consumables: recurrent revenue from reagents, kits and diagnostic instruments sold to laboratories and hospitals.

Livzon Pharmaceutical Group Inc. (1513.HK): How It Works

• Core revenue drivers: finished-dose drug sales, API/intermediate supply, diagnostic reagents & equipment, licensing and equity income from strategic investments.
• Distribution channels: direct hospital sales, pharmacy chains, public procurement, third‑party distributors, and exports to Europe/North America via licensing and direct sales.
• Value capture: proprietary formulations and high-barrier APIs (e.g., complex peptides, glycopeptides) plus diagnostic kits with stable recurring demand.

• Key strategic moves: equity investments in biotech (e.g., RMB1 billion capital contribution to LivzonBio in March 2025) to build upstream biologics pipelines and long‑term royalty/licensing income.
• Shareholder returns: final cash dividend declared June 2024 - HKD 14.8203 per 10 shares for the year ended 31 December 2023.

• Typical revenue composition (operational view): finished-dose products + hospital tenders (lead), APIs/intermediates (stable bulk revenue), diagnostics (high margin per kit in public health settings), and cross-border licensing/exports (growth focus).
• Margins and cashflow drivers: proprietary/complex APIs and biologics-related assets tend to command higher gross margins; tenders and mass-market generics are lower‑margin but volume‑stable.

• Leuprorelin acetate microspheres: developed, registered, manufactured and sold to hospitals and specialties-revenue from unit sales and repeat cycles for long‑acting therapy.
• Vancomycin hydrochloride & daptomycin APIs: bulk sales to other pharmas and export contracts; margins driven by scale and regulatory approvals for GMP‑certified production.
• Diagnostic kits: one‑time instrument sales plus recurring reagent kit consumables and service contracts that create predictable annuity‑type income.
• LivzonBio investment (RMB1 billion, Mar 2025): positions group to monetize biologics via internal development, licensing deals, or equity returns as pipeline assets mature.

Livzon Pharmaceutical Group Inc. (1513.HK): How It Makes Money

• Market capitalization: HKD 33.09 billion (as of December 12, 2025).
• Trailing P/E ratio: 14.13; Forward P/E ratio: 13.57.
• Net profit attributable to parent (first 3 quarters of 2025): ¥1.754 billion, up 4.86% YoY.
• Revenue (first 3 quarters of 2025): ¥9.116 billion, up 0.38% YoY.

• Core revenue streams:
  • Sales of small-molecule generics and branded prescription drugs across therapeutic areas.
  • Biological products and biosimilars developed and commercialized through LivzonBio and related entities.
  • Licensing, out-licensing and collaborations (royalties, milestone payments).
  • Contract development and manufacturing (CDMO) and CRO services for third parties.
• Strategic growth drivers:
  • Increased stake in LivzonBio to capture upside from biologics and oncology/immunology pipelines.
  • Development of a generic version of semaglutide to address a large diabetes/obesity market and potentially drive high-margin sales if approved and commercialized.
  • Continued R&D focus on unmet clinical needs, supporting innovation-led products with longer commercial lifecycles.